Preeclampsia Clinical Trial
Official title:
Expression of miRNA-452 in Patients With Early Onset Preeclampsia and Its Correlation With MMP-9
Preeclampsia is a pregnancy related disease characterized by the new onset of hypertension and proteinuria after 20 weeks of gestation in previously normotensive women. PE is one of the most challenging diseases in obstetrics worldwide that affects 2-8 % of pregnancies causing both morbidity and mortality of both mother and fetus.
The etiology and pathophysiology of preeclampsia are still unclear but the impaired invasive
ability of the trophoblast cells of the placenta and vascular endothelial cell damage are the
main two factors. The invasiveness of trophoblast cells depends on the production of
proteases, particularly matrix metalloproteinases (MMP). MMPs are a family of 24 zinc
dependent endopeptidases capable of degrading extra cellular matrix components. MMP-9 plays
an important role in placental invasion and implantation.
MicroRNAs (miRs) are a class of small (19-24 nucleotides in length), single-stranded,
non-protein-coding RNAs, which suppress translation or promote the degradation of target
messenger RNAs (mRNAs) and thus play an important role in the regulation of cell
proliferation, differentiation, apoptosis and even development of cancer.
The role of miRNA in preeclampsia pathogenesis has been investigated in a number of studies.
One of the target areas of the miRNAs that forms a link with preeclampsia pathogenesis is the
dysregulation of trophoblast differentiation, proliferation, and invasion; this occurs during
early pregnancy and leads to the development of preeclampsia; a range of miRNAs have been
confirmed to play pivotal roles in these processes by targeting a number of different genes.
MiR-452 is a newly discovered cancer related type of miRNA that was shown to be involved in
invasion process where it was upregulated in certain types of cancer such as blad¬der cancer,
urothelial carcinoma, and hepatocellular carcinoma and was found to be significantly
decreased in other types of cancer such as non-small cell lung cancer , glioma, prostate
cancer and Gastric cell cancer.
Based on these previous studies which demonstrate the effect of miR-452 in invasion process
of cancer cells either by stimulation or inhibition and that preeclampsia is a disease of
impaired placental invasion in which MMP-9 play an important role, we will investigate the
placental tissues expression changes of miR-452 which is not studied yet in early onset
preeclampsia patients compared to control and try to find a possible mechanism by which it
act on placental invasion by measuring expression level of MMP-9 and making correlation
between them. The results of this study will provide experimental and theo¬retical basis for
clinical prediction, prevention and treatment of preeclampsia.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03510286 -
Validation of a PrCr Dipstick Diagnostic Test in Ghana
|
||
Recruiting |
NCT03313024 -
Berlin-Brandenburg Pregnancy Cohort
|
||
Active, not recruiting |
NCT04990141 -
Molecular Screening Method for Preeclampsia (PREMOM)
|
||
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT05999851 -
Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy
|
N/A | |
Recruiting |
NCT02923206 -
Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis
|
N/A | |
Completed |
NCT02554604 -
Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
|
||
Not yet recruiting |
NCT02541110 -
Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler
|
N/A | |
Terminated |
NCT02558023 -
The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine
|
Phase 3 | |
Completed |
NCT02384226 -
User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
|
||
Completed |
NCT02854501 -
Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
|
||
Withdrawn |
NCT05016440 -
Lisinopril for Renal Protection in Postpartum Preeclamptic Women
|
N/A | |
Recruiting |
NCT02337049 -
Preeclampsia Subtypes and Surrogate Markers of CVD Risk
|
N/A | |
Recruiting |
NCT02247297 -
Pancreatic Stone Protein (PSP) in Pregnant Women
|
||
Completed |
NCT02238704 -
Cornell University-Micronutrient Initiative Calcium Supplementation Study
|
N/A | |
Completed |
NCT01195441 -
Prediction and Prevention of Preeclampsia by First Trimester Ultrasound
|
N/A | |
Withdrawn |
NCT01179542 -
The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR
|
N/A | |
Completed |
NCT00456118 -
Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
|
||
Recruiting |
NCT00117546 -
Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
|
Phase 4 | |
Completed |
NCT00787241 -
Platelet Count Trends in Pre-eclamptic Parturients
|
N/A |